A detailed history of Abrdn PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Abrdn PLC holds 329,338 shares of ETNB stock, worth $3.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
329,338
Previous 470,387 29.99%
Holding current value
$3.19 Million
Previous $3.48 Million 27.41%
% of portfolio
0.0%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 24, 2025

SELL
$7.03 - $10.05 $991,574 - $1.42 Million
-141,049 Reduced 29.99%
329,338 $2.53 Million
Q1 2024

May 08, 2024

BUY
$8.13 - $13.77 $2.08 Million - $3.53 Million
256,195 Added 119.61%
470,387 $5.48 Million
Q4 2023

Jan 31, 2024

BUY
$6.66 - $16.03 $1.43 Million - $3.43 Million
214,192 New
214,192 $2.39 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $450M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.